Wegovy, Ozempic, Zepbound, costs, risks, and competition
These medicines are booming in the U.S., uptake is slower in Europe, their cost, their key risks, and who’s competing with who.
What they are
Wegovy (semaglutide) and Zepbound (tirzepatide) are once-weekly injections that act on gut-hormone pathways to reduce appetite and improve metabolic control. Wegovy is semaglutide (same molecule as Ozempic, but approved and dosed for chronic weight management); Zepbound is a dual GIP/GLP-1 agonist. Both are approved in the U.S. for chronic weight management; Wegovy also has a cardiovascular-risk-reduction indication.
Why they’re so popular in the U.S.
- Access and coverage: Many large employers now cover GLP-1s for weight loss (often with prior authorization). Wegovy’s CV indication opened a path for some Medicare Part D coverage in people with obesity and established cardiovascular disease.
- Consumer pull + telehealth: Aggressive direct-to-consumer marketing and online clinics made it easy to get evaluated and prescribed, fueling demand even during shortages.
- Manufacturer programs: Companies offer discount channels or coupons that can materially lower out-of-pocket costs for some patients.
Why uptake is slower in Europe
- Stricter reimbursement: Many health systems fund anti-obesity medicines only for narrow groups and typically through specialist weight-management services.
- Gatekeeping and caps: Bodies like NICE (England) or HAS (France) tie use to specialist clinics, BMI thresholds, treatment failures, and time limits; capacity constraints slow rollout.
- Budget and supply protection: Several countries restrict use to control spend and preserve supply for diabetes care.
What they cost (examples)
- United States: Wegovy list price is roughly ~$1,300–$1,400/month, but manufacturer programs may drop costs (sometimes ~$500/month) for eligible patients; Zepbound pricing varies with dose and discounts. Actual out-of-pocket depends heavily on the plan.
- United Kingdom (private): Many online providers charge about £150–£250/month depending on dose; NHS access is via specialist pathways with confidential prices.
- France/Germany (illustrative): Roughly €270–€360/month in some private-pay scenarios in France (coverage tightly limited); German pharmacy quotes often rise by dose, with lower doses near the low-hundreds € and higher doses more.
Notes: Prices shift often, vary by dose and availability, and can change with insurer policies or national tenders.
Key risks & safety
- Boxed warning: GLP-1s carry a thyroid C-cell tumor warning based on rodent data; contraindicated with personal/family history of medullary thyroid carcinoma (MTC) or MEN2.
- Common GI effects: Nausea, vomiting, diarrhea, constipation; they slow gastric emptying (relevant before anesthesia).
- Pancreatitis & gallbladder: Stop and evaluate if suspected; gallstone-related issues can occur.
- Other cautions: Worsening diabetic retinopathy risk signals in some patients with diabetes, dehydration-related kidney injury, modest heart-rate increases. Avoid in pregnancy.
- Mood monitoring: Regulators have not found evidence of a causal link to suicidal ideation, but vigilance is advised.
Competition now and next
- Market leaders: Novo Nordisk (Wegovy/Saxenda) and Eli Lilly (Zepbound/Mounjaro). Across trials, tirzepatide often shows greater mean weight loss than semaglutide, but response and access vary by person and plan.
- Near-term pipeline: Oral GLP-1s (e.g., orforglipron) aim to remove injections; once-monthly agents (e.g., Amgen’s maridebart cafraglutide) target similar or greater efficacy with fewer injections; dual/triple agonists (e.g., retatrutide) are in late-stage development.
Bottom line
U.S. adoption is propelled by consumer demand, telehealth, and expanding (though uneven) coverage, plus Wegovy’s CV label. Europe is deliberately tighter, with HTA rules, specialist gateways, and budget constraints slowing uptake. Costs are high everywhere but vary widely by dose and coverage. Risks are well-characterized; most patients experience GI side effects, and specific contraindications apply. Competition is intensifying with new orals, once-monthly injections, and multi-agonist drugs on the way.